The disclosure comes as another of Arcus's TIGIT trials flops.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
The FDA throws out the company’s second attempt at an accelerated approval.
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.